Sugi Predict

Sugi Predict / Compounds / SCHEMBL1120039

SCHEMBL1120039

SCHEMBL1120039

Cc1ccc(S(=O)(=O)OCCC(C)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 2/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CA12 O43570 3/20 0.42
▸ CA9 Q16790 3/20 0.42
▸ CA1 P00915 3/20 0.42
▸ CA2 P00918 3/20 0.41
▸ GAA P10253 1/20 0.41
▸ CYP2D6 P10635 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ GBA1 P04062 1/20 0.39
▸ MMP1 P03956 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1660141 1.00 STAT3 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL3979818 1.00 STAT3 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL21239935 0.91 ALDH1A1 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL1681609 0.91 ALDH1A1 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL28641085 0.91 ALDH1A1 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL5991018 0.90 PSMD10 (0.42) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL5569851 0.90 STAT3 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL6936831 0.89 STAT3 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL6936829 0.89 STAT3 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL7020906 0.89 PSMD10 (0.41) STAT3ALDH1A1MEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4061834-A1 CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION Dana-Farber Cancer Institute, Inc. (US) 2022-09-28 — — EP claimed
US-20220281931-A1 CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-09-08 — — US claimed
WO-2021102283-A1 CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-05-27 — — WO claimed
EP-0472336-B1 Process for preparing optically active 3-hydroxybutane derivatives SUNTORY LTD (JP) 1996-11-06 — — EP claimed
US-5128264-A PROCESS FOR PREPARING OPTICALLY ACTIVE 3-HYDROXYBUTANE DERIVATIVES USING LIPASE SUNTORY LIMITED (JP) 1992-07-07 — — US claimed
EP-0472336-A1 Process for preparing optically active 3-hydroxybutane derivatives SUNTORY LIMITED (JP) 1992-02-26 — — EP claimed
EP-4737443-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Pharma Corporation (JP) 2026-05-06 — — EP disclosed
EP-3822276-B1 HETEROCYCLIC COMPOUND AS TRK INHIBITOR BEIJING INNOCARE PHARMA TECH CO LTD (CN) 2026-01-28 — — EP disclosed
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2025-11-20 — — US disclosed
EP-4536224-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE Blossomhill Therapeutics, Inc. (US) 2025-04-16 — — EP disclosed
US-20250074890-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-03-06 — — US disclosed
CN-119421709-A Indazole-containing macrocyclic compounds and uses thereof 荣山医药股份有限公司 2025-02-11 — — CN disclosed
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2025-01-30 — — US disclosed
US-5264443-A Psychotropic drugs, antidepressants and anxiolytic agents DELALANDE S.A. (FR) 1993-11-23 — — US disclosed
US-5196543-A Antidepressants, tranquilizers DELALANDE S.A. (FR) 1993-03-23 — — US disclosed
US-5171747-A Anxiolytic agents, antidepressants DELALANDE S.A. (FR) 1992-12-15 — — US disclosed
US-5128264-A PROCESS FOR PREPARING OPTICALLY ACTIVE 3-HYDROXYBUTANE DERIVATIVES USING LIPASE SUNTORY LIMITED (JP) 1992-07-07 — — US disclosed
EP-0490407-A2 Process for the enzymatic separation of the optical isomers of tosyloxy-alkanols MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) 1992-06-17 — — EP disclosed
EP-0472336-A1 Process for preparing optically active 3-hydroxybutane derivatives SUNTORY LIMITED (JP) 1992-02-26 — — EP disclosed
US-5036091-A Psychotropic drugs DELALANDE S.A. (FR) 1991-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074890-A1 CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS BCL6, BCL6B, BCOR STAT3 640/4885ALDH1A1 2828/4885MEN1 3100/4885
US-20250353864-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE AADAC, PAICS, CYP3A43 STAT3 2253/4885ALDH1A1 2230/4885MEN1 902/4885
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 STAT3 4817/4885ALDH1A1 1647/4885MEN1 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.